Wash. Says Novartis Isn't Harmed By 340B Drug Pricing Law
Washington is objecting to Novartis' attempt to block a state law that expands the discounts the drugmaker must provide under the federal 340B Drug Pricing Program, telling a federal court that worry about...To view the full article, register now.
Already a subscriber? Click here to view full article